NDA 214665 · Amgen INC
Lumakras
Sotorasib · Oral
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, May 28, 2021: To treat types of non-small cell lung cancer
Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
May 28, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
67
5 Phase 3, 17 recruiting
FAERS reports
3,470
2,851 serious, 824 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 3, 2026.
LUMAKRAS is an inhibitor of the RAS GTPase family indicated for: KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. ( 1.2 ) 1.1 KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) LUMAKRAS as a single agent is indicated for the treatment of adult patients with KRAS G12C -mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test [see Dosage and Administration (2.1) ] , who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) LUMAKRAS, in combination with panitumumab, is indicated for the treatment of adult patients with KRAS G12C -mutated metastatic...
Mechanism: Sotorasib is an inhibitor of KRAS G12C, a tumor-restricted, mutant-oncogenic form of the RAS GTPase, KRAS. Sotorasib forms an irreversible, covalent bond with the unique cysteine of KRAS G12C, locking the protein in an inactive state that prevents downstream signaling without affecting wild-type KRAS. Sotorasib blocked KRAS signaling, inhibited cell growth, and promoted apoptosis only in KRAS G12C tumor cell lines. Sotorasib inhibited KRAS G12C in vitro and in vivo with minimal detectable off-target activity. In mouse tumor xenograft models, sotorasib-treatment led to tumor regressions and...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 16, 2025 Supplement 9 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- May 28, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
3 products under this application
- LUMAKRAS · SOTORASIB 320MG · TABLET, ORAL · Prescription
- LUMAKRAS · SOTORASIB 240MG · TABLET, ORAL · Prescription
- LUMAKRAS · SOTORASIB 120MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sotorasib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
AmgenAmgen (AMGN)
NCT05920356 · 750 participants (planned) · Start Nov 16, 2023 · Primary completion Jun 30, 2027
Drug: Sotorasib; Pembrolizumab · For: Non-Small Cell Lung Cancer (NSCLC)
Sites: Santa Barbara, California; Newark, Delaware; Coral Springs, Florida · 418 sites in all
- A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03600883 · 713 participants · Start Aug 27, 2018 · Primary completion May 29, 2026
Drug: sotorasib; Anti PD-1/L1 and 1 more · For: KRAS p.G12C Mutant Advanced Solid Tumors
Sites: Duarte, California; Los Angeles, California; San Francisco, California · 133 sites in all
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruiting
AmgenAmgen (AMGN)
NCT04185883 · 610 participants · Start Dec 17, 2019 · Primary completion Dec 17, 2026
Drug: Sotorasib; Trametinib and 14 more · For: Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Sites: Tucson, Arizona; Duarte, California; La Jolla, California · 90 sites in all
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT06252649 · 450 participants (planned) · Start Jul 17, 2024 · Primary completion Sep 25, 2028
Drug: FOLFIRI Regimen; Sotorasib and 2 more · For: Metastatic Colorectal Cancer
Sites: Chandler, Arizona; Fullerton, California; Long Beach, California · 291 sites in all
- Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT04303780 · 345 participants · Start Jun 4, 2020 · Primary completion Aug 2, 2022
Drug: AMG 510; Docetaxel · For: KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Sites: Anaheim, California; Duarte, California; Long Beach, California · 274 sites in all
- A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06497556 · 338 participants · Start Sep 23, 2024 · Primary completion May 19, 2026
Drug: Divarasib; Sotorasib and 1 more · For: Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer
Sites: Gilbert, Arizona; Los Angeles, California; San Francisco, California · 151 sites in all
Federation Francophone de Cancerologie DigestiveAcademic, hospital or other
NCT07124884 · 300 participants (planned) · Start Aug 31, 2025 · Primary completion Jun 30, 2030
Drug: Administration of experimental treatment association (sotorasib, panitumumab 5FU) · For: Colorectal Carcinoma; KRAS G12C Mutation; Unresectable Colorectal Cancer
Sites: Angers, France; Annecy, France; Antony, France · 80 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- non-small cell lung cancer520
- death415
- disease progression348
- diarrhoea334
- off label use268
- fatigue119
- nausea119
- hepatotoxicity103
- hepatic function abnormal101
- non-small cell lung cancer metastatic98
- lung neoplasm malignant85
- alanine aminotransferase increased81
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 198 |
| 2022 | 714 |
| 2023 | 1,226 |
| 2024 | 545 |
| 2025 | 381 |
| 2026 | 406 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lumakras (Sotorasib)
2024 spending
$154M
Beneficiaries
1,563
8,675 claims
Per beneficiary
$98,285
$146.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $35,800,207 |
| 2022 | $123,593,806 |
| 2023 | $140,234,716 |
| 2024 | $153,620,121 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.
Fakih MG, Salvatore L, Esaki T, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Multicenter Study
- Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
de Langen AJ, Johnson ML, Mazieres J, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Skoulidis F, Li BT, Dy GK, et al. · N Engl J Med 2021 · Clinical Trial, Phase II, Multicenter Study
- Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.
Strickler JH, Satake H, George TJ, et al. · N Engl J Med 2023 · Clinical Trial, Phase I, Clinical Trial, Phase II
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
Hong DS, Fakih MG, Strickler JH, et al. · N Engl J Med 2020 · Clinical Trial, Phase I, Multicenter Study
- Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.
Kuboki Y, Fakih M, Strickler J, et al. · Nat Med 2024 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.